Aristotle University Of Thessaloniki (AUTH)
Θεραπευτικές προτεραιότητες ασθενών, ιατρών και κλινικής έρευνας στο πολλαπλούν μυέλωμα
Abstract
dc:descriptionThe aim of this study was to map the endpoints used in randomized controlled trials (RCTs) in multiple myeloma and to evaluate the extent to which these endpoints align with the priorities of patients and clinicians. In parallel, areas of convergence and divergence among stakeholders were explored, with the goal of identifying opportunities for implementing a patient-centered approach in research and clinical practice. The study was conducted in two sequential stages. First, a systematic review of all randomized controlled trials in multiple myeloma published in English up to October 2023 was performed, including studies evaluating therapeutic interventions for the disease itself as well as supportive care interventions. This was followed by a regression analysis to identify factors associated with endpoint selection. In the second stage, a mixed-methods study was conducted, combining qualitative interviews with patients and clinicians and quantitative surveys to compare outcome priorities. Among the 624 RCTs included, the most frequently reported primary endpoint was disease response, followed by progression-free survival (PFS) and overall survival. Overall survival was used as a primary endpoint in 19.1% of trials and as a secondary endpoint in 50.6%. Trials funded by the pharmaceutical industry were more likely to use PFS as the primary endpoint (OR 3.85; 95% CI 2.41-6.35), as were trials in which authors reported conflicts of interest with the funding source (OR 4.57; 95% CI 2.72-7.92). The surveys were completed by 117 patients and 105 clinicians. Both groups ranked quality of life as the most important outcome. Clinicians more frequently prioritized overall survival and PFS, whereas patients identified pain reduction as particularly important. Compared with RCT endpoints, patients emphasized quality of life and pain elimination, while trials favored PFS and disease response. Clinicians aligned with trials regarding PFS but placed greater emphasis on quality of life and overall survival. These findings reveal a misalignment between the endpoints used in multiple myeloma clinical research and patient priorities. Although surrogate endpoints offer practical advantages, their dominance risks de-emphasizing outcomes of greatest relevance to patients. This study supports the need for a more balanced trial design, ensuring that clinical research addresses meaningful questions that matter to patients.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Mainou, Maria
- Μάινου, Μαρία
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61677